| Structural highlights
2bst is a 3 chain structure with sequence from Homo sapiens and Influenza a virus. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance.
| | Related: | 1a1m, 1a1n, 1a1o, 1a6z, 1a9b, 1a9e, 1agb, 1agc, 1agd, 1age, 1agf, 1akj, 1ao7, 1b0g, 1b0r, 1bd2, 1c16, 1ce6, 1cg9, 1de4, 1duy, 1duz, 1e27, 1e28, 1eey, 1eez, 1efx, 1exu, 1gzp, 1gzq, 1hhg, 1hhh, 1hhi, 1hhj, 1hhk, 1hla, 1hsa, 1hsb, 1i1f, 1i1y, 1i4f, 1i7r, 1i7t, 1i7u, 1im3, 1im9, 1jf1, 1jgd, 1jge, 1jht, 1jnj, 1k5n, 1kpr, 1ktl, 1lds, 1lp9, 1m05, 1m6o, 1mhe, 1mi5, 1n2r, 1of2, 1oga, 1ogt, 1onq, 1p7q, 1py4, 1q94, 1qew, 1qlf, 1qqd, 1qr1, 1qrn, 1qse, 1qsf, 1qvo, 1r3h, 1rog, 1roh, 1roi, 1roj, 1rok, 1rol, 1s9w, 1s9x, 1s9y, 1sys, 1syv, 1tmc, 1tvb, 1tvh, 1uqs, 1ur7, 1uxs, 1uxw, 1w0v, 1w0w, 1w72, 1xh3, 1xr8, 1xr9, 1xz0, 1ydp, 1ypz, 2bnq, 2bnr, 2bsr, 2bss, 2clr, 2hla, 3hla |
| Resources: | FirstGlance, OCA, RCSB, PDBsum |
Disease
[1B27_HUMAN] Defects in HLA-B are a cause of susceptibility to spondyloarthropathy type 1 (SPDA1) [MIM:106300]. It is a chronic rheumatic disease with multifactorial inheritance. It includes a spectrum of related disorders comprising ankylosing spondylitis, a subset of psoriatic arthritis, reactive arthritis (e.g. Reiter syndrome), arthritis associated with inflammatory bowel disease and undifferentiated spondyloarthropathy. These disorders may occur simultaneously or sequentially in the same patient, probably representing various phenotypic expressions of the same disease. Ankylosing spondylitis is the form of rheumatoid arthritis affecting the spine and is considered the prototype of seronegative spondyloarthropathies. It produces pain and stiffness as a result of inflammation of the sacroiliac, intervertebral, and costovertebral joints. Note=In the Greek Cypriot population, a restricted number of HLA-B27 subtypes are associated with ankylosing spondylitis and other B27-related diseases and an elevated frequency of the B*2702 allele in ankylosing spondylitis patients is identified. The allele B*2707 seems to have a protective role in this population because it was found only in the healthy controls.[1]
Function
[1B27_HUMAN] Involved in the presentation of foreign antigens to the immune system.
Evolutionary Conservation
Check, as determined by ConSurfDB. You may read the explanation of the method and the full data available from ConSurf.
Publication Abstract from PubMed
We have solved the crystal structures of three HLA-B*2705-peptide complexes with the immunodominant viral peptides: EBV EBNA3C 258-266 (RRIYDLIEL), influenza (flu) nucleoprotein NP383-391 (SRYWAIRTR), and HIV gag 264-273 (KRWIILGLNK). Long-term non-progression during HIV infection has been associated with presentation by HLA-B*2705, and T cell recognition, of the highly immunodominant KRWIILGLNK peptide. The tight hydrogen-bonding network observed between the HLA-B*2705 B-pocket and the peptide P2 arginine guanadinium anchor explains why mutation of this residue during HIV infection results in loss of peptide binding, immune escape and progression to AIDS. Prominent, solvent-exposed structures within these peptides may participate in generating T cell responses to these immunodominant epitopes. In the HLA-B*2705 complex with flu NP383-391, the amino acid side chains of residues 4, 7 and 8 are solvent-exposed whilst in the HIV decamer, the main-chain bulges into the solvent around P7. Thus, HLA-B*2705 presents viral peptides in a range of conformations. Tetrameric complexes of HLA-B*2705 with the HIV and flu but not EBV peptides bound strongly to the killer-Ig-like receptor (KIR)3DL1. Substitution of EBV P8 glutamate to threonine allowed recognition by KIR3DL1. In the HLA-B*2705-EBV structure the P8 glutamate side chain is solvent-exposed and may inhibit KIR3DL1 binding through electrostatic forces.
Crystal structures and KIR3DL1 recognition of three immunodominant viral peptides complexed to HLA-B*2705.,Stewart-Jones GB, di Gleria K, Kollnberger S, McMichael AJ, Jones EY, Bowness P Eur J Immunol. 2005 Feb;35(2):341-51. PMID:15657948[2]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
See Also
References
- ↑ Varnavidou-Nicolaidou A, Karpasitou K, Georgiou D, Stylianou G, Kokkofitou A, Michalis C, Constantina C, Gregoriadou C, Kyriakides G. HLA-B27 in the Greek Cypriot population: distribution of subtypes in patients with ankylosing spondylitis and other HLA-B27-related diseases. The possible protective role of B*2707. Hum Immunol. 2004 Dec;65(12):1451-4. PMID:15603872 doi:10.1016/j.humimm.2004.08.177
- ↑ Stewart-Jones GB, di Gleria K, Kollnberger S, McMichael AJ, Jones EY, Bowness P. Crystal structures and KIR3DL1 recognition of three immunodominant viral peptides complexed to HLA-B*2705. Eur J Immunol. 2005 Feb;35(2):341-51. PMID:15657948 doi:10.1002/eji.200425724
|
